phosphatase/atrophy

This application is the Nation Stage of International Application NO. PCT/EP2003/01575, filed Sep. 23, 2003. The present invention relates to a novel vitamin B.sub.6 phosphate phosphatase (VB6P phosphatase) gene, recombinant microorganisms transformed with a vector having the gene, and a polypeptide

FIELD OF THE INVENTION The present invention relates to the use of alkaline and acid phosphatase inhibitors in the treatment of neurological disorders. More particularly, the present invention relates to the use of various specific phosphatase inhibitors in the treatment of .beta.-amyloid toxicity

The present invention relates to the use of carprofen in mammals as a means of treating and preventing cartilage and subchondral bone injury and loss in the inflamed joints of such mammals. Such damage to the cartilage and subchondral bone is a natural sequelae of the process of osteoarthritis and

BACKGROUND OF THE INVENTION The immunosuppressant drugs cyclosporin A and FK506 are thought to exert their therapeutic effects by binding to receptor proteins, designated cyclophilins and FK506 binding proteins (FKBP) respectively. When complexed to the immunosuppressant drugs, these binding

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the treatment of tauopathies and, more specifically, the use of mGluR5 antagonists for the treatment of tau pathologies. 2. Description of the Related Art Indigenous residents and immigrants of the Pacific Island

BACKGROUND OF THE INVENTION The immunosuppressant drugs cyclosporin A and FK506 are thought to exert their therapeutic effects by binding to receptor proteins, designated cyclophilins and FK506 binding proteins (FKBP) respectively. When complexed to the immunosuppressant drugs, these binding

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority of Korean Patent Applications Nos. KR 10-2015-0100430, filed Jul. 15, 2015 and KR 10-2015-0100481, filed Jul. 15, 2015, the contents of each of which are hereby incorporated by reference into the application. REFERENCE TO A